Bicycle Therapeutics Q1 FY26 net loss holds at USD 60.8 million; revenue drops to USD 0.9 million

• Bicycle Therapeutics posted a Q1 net loss of 60.8 million, or $(0.87) per share.
• Revenue fell 91.1% to 887,000.
• Operating loss narrowed to 65.5 million on lower R&D and G&A costs.
• Cash and cash equivalents declined to 559.5 million as of March 31, 2026.
• Pipeline update highlighted first patient dosed in Phase 2 PDAC trial of nuzefatide pevedotin; preferred dose set at 8 mg/m² Q2W.
• Strategic reprioritization included converting Duravelo-2 into a randomized Phase 2 trial, shutting enrollment for Duravelo-3 and Duravelo-4, and cutting workforce about 30%.
• Management said actions should cut annual operating expenses about 50% and extend cash runway into 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260430332492) on April 30, 2026, and is solely responsible for the information contained therein.